ALPMF News 10.4900 Astellas Pharma Inc (ALPMF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMF) 10.4900 $ALPMF

Japan Pharmaceutical Market Outlook 2013-2019 - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment
M2 - Fri Apr 11, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp5lfl/japan) has announced the addition of the "Japan Pharmaceutical Market Outlook 2013-2019 - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment" report to their offering. Japan's pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%. Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the increase of drug prices. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use. However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing market share of generics may dampen market value, this represents a great deal of opportunity for generic manufacturers. Historically, the Japanese pharmaceutical market has favored domestic companies. However, since the 1990s, deregulation has promoted investment from abroad and increased the presence of foreign firms. Scope - The report assesses characteristics of the Japanese pharmaceutical market, detailing recent regulatory changes, supply chain and competitive - landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy. - A macroeconomic analysis of Japan, focusing on key economic parameters such as Gross Domestic Product (GDP), inflation and unemployment. The implications of the global financial crisis in 2008 and natural disaster in 2011 are considered. - The changing demographic landscape and implications on health economics and policy-making. - The industry characteristics section presents an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan. Notable changes that have occurred over recent years, in an attempt to improve the regulatory system and reduce drug review times, are highlighted. - The report then analyzes the competitive landscape in Japan, including the major domestic companies and M&A. The discussed regulatory reforms and cooperation between government and industry have improved the international competitiveness of Japan's pharmaceutical market. Coupled with a number of mergers, the industry now consists of well-known multinationals. The competitive landscape section confirms the top five Japanese pharmaceutical companies by revenue, according to GBI Research data. - The report concludes by providing an overview of the drivers and barriers currently facing the Japanese pharmaceutical industry. Key Topics Covered: - Tables & Figures - Introduction - Market Overview - Industry Characteristics - Competitive Landscape - Drivers and Barriers - Japan Pharmaceutical Market Outlook - Appendix Companies Mentioned - Astellas Pharma Inc. - Daiichi Sankyo Ltd. - Eisia Ltd. - Otsuka Holdings Ltd. - Takeda Pharmaceutical Ltd. For more information visit http://www.researchandmarkets.com/research/sp5lfl/japan

Thought Leaders are Optimistic that Emerging Therapies will Offer Efficacy Benefits Over Current Therapies for Metastatic Gastric Cancer; Augmenting Biomarker-Driven Prescribing
PR Newswire - Thu Apr 10, 12:00PM CDT
Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and Roche/Genentech/Chugai's Kadcyla will join Roche/Genentech/Chugai's Herceptin in the HER2-targeted treatment armamentarium for metastatic gastric cancer. Moreover, oncologists express enthusiasm for c-Met overexpression as a predictive biomarker in metastatic gastric cancer, and anticipate that rilotumumab (Amgen/Astellas Pharma) and onartuzumab (Roche/Genentech/Chugai), both in combination with chemotherapy, will demonstrate efficacy advantages over chemotherapy alone. Interviewed physicians also expressed enthusiasm for the angiogenesis inhibitor ramucirumab (Eli Lilly/ImClone Systems), based on positive Phase III data from the REGARD and RAINBOW trials.

Global Asthma Therapeutics Market 2013-2019 - Analysis of the $21 Billion Industry
M2 - Thu Apr 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/srkrc5/asthma) has announced the addition of the "Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth" report to their offering. Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline's (GSK's) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). These include reslizumab, mepolizumab and lebrikizumab, which are being developed by Teva, GSK and Roche respectively. The mAbs, in particular, have the potential to change the asthma treatment landscape, most notably with regards to severe forms of the disease. Although such therapy may only play the role of an alternative treatment in the asthma treatment algorithm, their ability to reduce exacerbation rates has strong clinical and commercial value. SCOPE - A disease introduction, which defines the disease, including symptoms, diagnosis and treatment - Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands - Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs. - An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. - Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements - An overview of the drivers and barriers for the asthma market Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Asthma Pipeline - Market Forecast to 2019 - Strategic Consolidations - Appendix Companies Mentioned - Astellas Pharma Inc - AstraZeneca - Genentech - GlaxoSmithKline - Merck & Co - Novartis - Schering Corporation - Theravance For more information visit http://www.researchandmarkets.com/research/srkrc5/asthma

Global Chronic Obstructive Pulmonary Disease (COPD) Market 2013-2019
M2 - Thu Apr 10, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t57wdh/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth" report to their offering. The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition. Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period. Scope - A disease introduction, which defines the disease, including symptoms, diagnosis and treatment. - An analysis of the COPD marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map. - A detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action. - An in-depth forecasting model for the COPD market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, costs and patent expirations. - Strategic consolidations within the COPD indication are analyzed, which includes co-development and licensing agreements. - An overview of the drivers and barriers for the COPD market is also included. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - COPD Pipeline - Market Forecast to 2019 - Strategic Consolidations - Appendix Products Mentioned - Advair Diskus - GlaxoSmithKline - Arcapta/Onbrez Breezhaler - Novartis - Combivent- Boehringer Ingelheim - Daliresp - Nycomed - Foradil - Novartis (Co-marketed by Novartis and Schering Corporation) - Relvar/Breo - GlaxoSmithKline/Theravance - Seebri Breezhaler - Novartis - Spiriva - Boehringer Ingelheim Pharmaceuticals, Pfizer Inc. - Striverdi Respimat - Boehringer Ingelheim - Symbicort - AstraZeneca (Co-promotion with Astellas Pharma Inc) For more information visit http://www.researchandmarkets.com/research/t57wdh/chronic

Astellas Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
PR Newswire - Thu Apr 03, 6:00AM CDT
Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. XTANDI is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy.

Astellas Announces Marketing Authorisation Application for XTANDI(TM) (enzalutamide) for Chemotherapy-Naive Metastatic Prostate Cancer
PR Newswire Europe - Thu Apr 03, 2:05AM CDT
TOKYO, April 3, 2014 /PRNewswire/ --

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone

NCCN Receives $2.2 Million in Research Funding From Astellas and Medivation to Study Enzalutamide in Solid Tumors
Marketwire - Mon Mar 31, 12:00PM CDT
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.

Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Thomson Reuters ONE - Thu Mar 27, 6:31AM CDT
Commencement of Study Triggers Milestone Payment from Astellas

Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment
PR Newswire - Mon Mar 24, 3:10PM CDT
Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI® capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013.

Astellas and Medivation submits sNDA to the US FDA for XTANDI
M2 - Wed Mar 19, 7:26AM CDT
Japanese pharmaceutical company Astellas Pharma (TSE:4503) and US-based Medivation (NASDAQ:MDVN) reported on Tuesday the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for XTANDI capsules for treating men with metastatic castration-resistant prostate cancer (mCRPC) who have not undergone chemotherapy.

Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
PR Newswire - Tue Mar 18, 11:30PM CDT
Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been formed in Japan.

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer
Marketwire - Tue Mar 18, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI(R) (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.

American Urological Association And Astellas Team Up To Secure The Future Of Urology Research Through $3 Million Endowment
PR Newswire - Thu Mar 13, 9:00AM CDT
The American Urological Association (AUA) and Astellas US LLC, a U.S. affiliate of Tokyo-based Astellas Pharma Inc., have announced a $3 million commitment to the Urology Care Foundation and to the promising young urologists seeking careers in academic urology.

Research and Markets: Investigation Report on China's Tacrolimus Market, 2009-2018
Business Wire - Mon Mar 10, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcjjqn/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering.

Investigation Report on China's Tacrolimus Market, 2009-2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qv9pgq/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name ""Prograf"". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China. Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly. For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value. Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus. Key Topics Covered: 1 Relevant Concept of Tacrolimus 2 Market Overview of Tacrolimus in China 3 Investigation on Sales Value of Tacrolimus in China, 2009-2013 4 Investigation on Market Share of Major Tacrolimus Manufacturers in China, 2009-2013 5 Investigation on Market Size of Tacrolimus by Dosage Form in China, 2009-2013 6 Reference Price of Tacrolimus in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Tacrolimus Market, 2009-2013 8 Prospect of China Tacrolimus Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/qv...estigation

Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.

Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.

Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas" announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea" . Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 132

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 214

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 252

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 173

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Insmed to Discuss Financial Results in Upcoming Conference Call

Updated Category News Views 149

Insmed Financial Results Conference Call Announcement Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on delivering innovative therapies, has announced an important event for investors and stakeholders. The company is set to release its second-quarter financial results, and the details are crucial for those following its progress in the healthcare...

Continue Reading
Rathbones Group Plc Details on Renewi Plc Securities Disclosure

Updated Category News Views 202

Important Disclosure on Securities Related to Renewi Plc Understanding corporate disclosures is crucial for investors and stakeholders in any market. This article aims to highlight significant details surrounding Rathbones Group Plc's interest in the securities of Renewi Plc, a leading player in the waste management industry. Rathbones, known for its long-standing...

Continue Reading
Nuo Therapeutics Teams Up with Smith+Nephew for Innovative Wound Care Solutions

Updated Category News Views 436

Nuo Therapeutics Signs Exclusive Distribution Deal with Smith+Nephew Nuo Therapeutics, Inc. (OTCQB: AURX) has recently made headlines with the announcement of a significant private label distribution agreement with Smith+Nephew, a leader in medical technology. This partnership marks an exciting new chapter for Nuo, as it strategically positions itself within the advanced...

Continue Reading
Russia's Ambitious Plan to Enhance Baltic Sea Ports by 2030

Updated Category News Views 266

So, here’s the scoop: Russia’s flexing its muscles on the global stage by ramping up its Baltic Sea port capabilities. They’re not just kicking back and letting things unfold; they’ve got a plan to jack up their agricultural exports by a whopping 50% by 2030. This move isn’t merely about exporting more wheat; it’s a strategic pivot aimed at cutting down...

Continue Reading
Collaborating for a Greener Future: Univers and Microsoft Join Forces

Updated Category News Views 189

Univers Partners with Microsoft to Transform Energy Efficiency Univers, a global pioneer in artificial intelligence and Internet of Things (IoT) technology dedicated to energy solutions, has made waves by announcing a new partnership with Microsoft. This collaboration aims to catalyze the shift towards sustainable energy using innovative AI and cloud solutions. Setting...

Continue Reading